|
|
| Attention Investors |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
Your results on : Equity | Company Profile | Detailed Quotes |
|
|
|
|
|
|
|
|
|
|
|
| Stock Price Details |
|
Chart |
|
| Last Price |
423.90 |
|
| Change |
0.00 (0.00%) |
|
| Best Buy |
0(x0) |
|
| Best Sell |
0(x0) |
|
| Today's Range |
412.00
- 445.40 |
|
| 52-Week Range |
215.55
- 511.00 |
|
|
|
1 Day
| 5 Day
| 3 Month
| 1 Year
| 5 Year
|
|
|
|
| News |
|
Corporate Details |
|
|
|
| Incorporation Year : 2017 |
|
| Chairman : |
|
| Ownership Group : Indian Private |
|
| Sector : MAN |
|
| Industry : Pharmaceuticals - Indian - Bulk Drugs & Formln |
|
| Registered Office |
|
Solara Active Pharma Sciences Ltd Partly Paidup 201 Devavrata Sector 17, Vashi Navi Mumbai, , Maharashtra-400703 |
|
Phone:91-22-27892924 Fax:91-22-27892942 |
|
| E-Mail : investors@solara.co.in |
|
| URL : http://www.solara.co.in |
|
|
|
| Investor Returns |
|
| |
|
Date |
|
Price (Rs) |
|
Returns (%) |
|
|
| 1Week |
03-Dec-2025 |
378.40 |
13.11 |
|
| 1Month |
10-Nov-2025 |
391.95 |
9.20 |
|
| 3Month |
10-Sep-2025 |
453.10 |
-5.54 |
|
| 6Month |
10-Jun-2025 |
331.50 |
29.11 |
|
| 1Year |
10-Dec-2024 |
491.65 |
-12.95 |
|
|
|
|
| Mutual Funds Holding |
|
| No Data Found |
|
|
|
|
| Groups : Pharmaceuticals - Indian - Bulk Drugs & Formln |
|
| Company |
|
Last Price(Rs) |
|
Change(%) |
|
52Week High(Rs) |
|
52Week Low(Rs) |
|
Market Cap(Rs Cr.) |
| Sun Pharmaceutical Industries Ltd |
1,776.90 |
-0.52 |
1,910.00 |
1,547.25 |
4,28,581.21 |
|
| Cipla Ltd |
1,495.10 |
0.40 |
1,672.20 |
1,310.05 |
1,20,289.25 |
|
| Dr Reddys Laboratories Ltd |
1,249.85 |
-0.10 |
1,404.60 |
1,025.90 |
1,04,420.60 |
|
| Lupin Ltd |
2,054.15 |
-0.04 |
2,403.45 |
1,774.00 |
93,866.91 |
|
| Zydus Lifesciences Ltd |
922.75 |
-0.10 |
1,059.00 |
797.05 |
92,945.83 |
|
|
|
|
|
|
|
| |
|
|
| |
| X |
| Filing complaints on SCORES |
| Easy & Quick |
| |
| › |
Register on SCORES Portal |
› |
Mandatory details for filing complaints on SCORES
| Name |
PAN |
Address |
Mobile No. |
Email ID |
|
| › |
Benefits: |
| |
|
|
|